REIMAGINE 2: New Phase 3 Data on Cagrilintide-Semaglutide in Type 2 Diabetes

Novo Nordisk’s investigational combination of cagrilintide and semaglutide — studied under the name CagriSema — has mostly been discussed on this blog in the context of weight-management research (the REDEFINE program). A trial published this month in The Lancet Diabetes & Endocrinology, REIMAGINE 2, shifts the lens to glycaemic control, comparing the fixed-dose combination directly against its two individual components in people with type 2 diabetes. It’s a useful addition to the literature because it isolates what the amylin-receptor component (cagrilintide) adds on top of GLP-1 receptor agonism alone, in a controlled head-to-head design rather than a comparison across separate trials.

Trial design, briefly

REIMAGINE 2 was a randomised, double-blind, phase 3 study run across 30 countries, enrolling 2,713 adults with type 2 diabetes that was inadequately controlled on metformin (with or without an SGLT2 inhibitor) and a BMI of 25 or higher. Participants were assigned to one of six arms: cagrilintide plus semaglutide at matched 2.4 mg doses, semaglutide alone at 2.4 mg, cagrilintide alone at 2.4 mg, a lower-dose combination (1.0 mg each), semaglutide alone at 1.0 mg, or placebo. Treatment ran for 68 weeks, with the primary comparison being HbA1c change at week 68 between the full-dose combination and semaglutide 2.4 mg alone.

This design matters for research purposes because it directly tests an additive hypothesis — whether pairing an amylin-receptor agonist with a GLP-1 receptor agonist produces a meaningfully better glycaemic outcome than the GLP-1 agent by itself, rather than inferring it indirectly from separate studies of each compound.

What the trial found

The study population had a mean baseline HbA1c of 8.2%. At 68 weeks, the full-dose combination arm showed a significantly larger HbA1c reduction than semaglutide alone — a between-group difference of roughly 0.16 percentage points, a modest but statistically significant margin given the trial’s size (p=0.0035). Completion rates were high (nearly 96% of participants finished the study), and the adverse-event profile in the combination arm tracked closely with what’s already been documented for GLP-1 receptor agonists as a class, with gastrointestinal effects being the most commonly reported issue across all active-treatment groups.

The magnitude of the difference is worth sitting with rather than glossing over: this was not a dramatic separation between arms, and the trial’s own framing describes it as an incremental rather than transformative improvement in glycaemic control when cagrilintide is added to semaglutide. That’s a meaningfully different message than the larger effect sizes reported in CagriSema’s weight-management trials, and it’s a reminder that a combination’s benefit can vary by which outcome — bodyweight versus HbA1c — is being measured.

Where this fits in the broader CagriSema research program

REIMAGINE 2 is part of a parallel trial track to REDEFINE, which has focused on bodyweight outcomes in people with obesity. Together, the two programs are building out a more complete picture of what combined amylin/GLP-1 receptor agonism does across different metabolic endpoints, in different patient populations, rather than treating “weight loss” and “glycaemic control” as a single outcome driven by the same mechanism. For anyone tracking the amylin-agonist research space specifically, this trial is a good example of how that mechanism is being evaluated on its own terms — as a complement to GLP-1 agonism for glucose handling, not just as a bodyweight adjunct.

What this means for ongoing research

REIMAGINE 2 adds controlled, head-to-head evidence to a growing dataset on fixed-dose amylin/GLP-1 combinations, and it’s a useful reference point for anyone comparing the cagrilintide-semaglutide combination against single-agent GLP-1 therapy in a research context. As with all data on CagriSema, this remains an investigational combination — it is not an FDA-approved product, and the trial results describe a controlled clinical population under close medical supervision over 68 weeks, not a general-use protocol.

Further reading

• Buse JB, Bajaj HS, Dalskov SM, et al. “Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.” The Lancet Diabetes & Endocrinology, 2026;14(8):662-677. PubMed: 42251859 · doi.org/10.1016/S2213-8587(26)00125-7